COPD, stage and treatment in a large outpatient clinic
Some COPD patients suffer from frequent exacerbations despite triple inhalation treatment. These frequent exacerbators should be identified, as exacerbations often lead to decreasing lung function and increasing mortality. Roflumilast reduces exacerbations in patients with a previous history of exac...
Main Authors: | Claire Præst Holm, Jakob Holm, Annette Nørgaard, Nina Godtfredsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-01-01
|
Series: | European Clinical Respiratory Journal |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20018525.2017.1267470 |
Similar Items
-
Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
by: Calverley PMA, et al.
Published: (2017-11-01) -
Roflumilast: a review of its use in the treatment of COPD
by: Wedzicha JA, et al.
Published: (2016-01-01) -
The use of roflumilast in COPD: a review
by: Andrea Zanini, et al.
Published: (2015-08-01) -
The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype
by: Miłkowska-Dymanowska J, et al.
Published: (2018-11-01) -
Roflumilast is effective in reducing COPD related exacerbations and improving CAT score
by: Biagio Polla
Published: (2015-08-01)